MC
ANIP icon

Maverick Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Maverick Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,536
Closed -$1.18M – 237
2024
Q2 		$1.18M Buy
18,536
+13,926
+302% +$904K 0.02% 197
2024
Q1 		$319K Buy
+4,610
New +$278K 0.01% 338

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maverick Capital's ANIP Position: Q3 2024 in Review

Maverick Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2024, closing a stake of 18,536 shares — an estimated $1.18M sold.

Maverick Capital first reported a position in ANIP in Q1 2024 and held it in 2 quarters. The position peaked at $1.18M in Q2 2024. 208 funds tracked by Wall St. Rank hold ANIP as of Q3 2024.

  • Maverick Capital reported no remaining ANI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Maverick Capital sold 18,536 ANI Pharmaceuticals shares in Q3 2024, an estimated $1.18M.
  • Maverick Capital first reported a position in ANI Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Maverick Capital's ANI Pharmaceuticals position peaked at $1.18M in Q2 2024.
  • 208 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2024.

Based on Maverick Capital's 13F filing for Q3 2024, filed 14 Nov 2024.